NCT06780111
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
MRK — Merck & Co., Inc.
Phase 1, Phase 2
• Esophageal Squamous Cell Carcinoma
TL;DR
Enrollment 228→298 (31%) — PHASE1, PHASE2
What changed
- Enrollment: 228 → 298
Recent events (last 90 days)
2026-01-12
MEDIUM
Enrollment 228→298 (31%) — PHASE1, PHASE2
Phase 1, Phase 2 • Enrollment 228→298
2026-01-12
MEDIUM
Primary endpoint removed: Percentage of Participants Who Discontinue Study Intervention Due to an AE — PHASE1, PHASE2
Phase 1, Phase 2
What to check next
- Review CT.gov update history and company disclosures for context.
- Verify whether registry updates lag press releases.